Hormonal
GLP-1 receptor agonists significantly improve lipid profiles (reducing Total Cholesterol and LDL-C, increasing HDL-C) and fasting plasma glucose in obese individuals with psychotic disorders, but do not significantly affect waist circumference, systolic/diastolic blood pressure, or triglycerides.
GLP-1 receptor agonists improve blood sugar and cholesterol levels (lowering bad cholesterol and triglycerides, raising good cholesterol) in patients with psychotic disorders, but they do not significantly lower blood pressure or waist circumference. This makes them valuable for metabolic health, even if blood pressure remains unchanged.
A significant improvement in glycemia and lipid profiles was also demonstrated with GLP-1RAs. However, no significant effect on waist circumference was shown... GLP-1RA treatment compared to control resulted in a non-significant effect on office SBP... failed to produce a significant decrease in office DBP... GLP-1RA failed to provide a significant effect compared to control [on TRG].
Why this rating
Meta-analysis of RCTs with low risk of bias, though some metrics showed high heterogeneity or non-significance.
Source
Effect of Glucagon-like Peptide-1 Receptor Agonists on Cardio-Metabolic Risk Factors among Obese/Overweight Individuals Treated with Antipsychotic Drug Classes: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials
Dimitrios Patoulias et al. · Biomedicines · 2023
DOI 10.3390/biomedicines11030669
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →